Clinical Trial Search

Primary: Change in Mixed-meal-stimulated Peak C-peptide Value (Via Mixed-meal Tolerance Test) After 12 Months of Insulin Pump Therapy, Compared With MDI. — 1.8; 3.1 ng/mL

Primary: Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo — 0.088; 0.102 Proportion with diabetes/year

Primary: Area Under the Stimulated C-peptide Curve Over the First 2 Hours of a 4-hour Mixed Meal Tolerance Test (MMTT) Administered at 1 Year — 0.58; 0.429 pmol per mL — p=0.05

Primary: Mean Weekly Blood Glucose — 187; 178 mg/dL

Primary: Adverse Events — 2; 2 Serious adverse events

Primary: Feasibility of Usage — 168 minutes/week

Primary: The Role of Exenatide as Compared to Insulin Monotherapy in Reducing Postprandial Hyperglycemia.

Primary: Change From Baseline in 2-Hour C-peptide Mean Area Under the Curve (mAUC) in Pediatric Participants — -0.337; -0.391 pmol/mL — p=0.277

Primary: Insulin Sensitivity — 8.6; 6.2; 5.8; 4.8 mg/kg/min

Primary: Number of All Consented Participants — 12; 12 Participants

Primary: Area Under the Stimulated C-peptide Curve (AUC) Mean Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 1 Year Visit — 0.834; 0.775 nmol/L — p=0.048

Primary: Change From Baseline in Glucagon-Stimulated C-Peptide AUC at 24 Months — -5.20; -4.83 nmol*min/L — p=0.33

Primary: The Change From Baseline of DQ8 Antigen Presentation by Peripheral Blood Mononuclear Cells After 6 Weeks of Methyldopa Treatment. — 642; 430; 27.4; 17.9 pg/mL

Primary: Mean Change in the Percent of Time With Sensed Glucose Between 70 - 180 mg/dl — -3.8 percentage of time

Primary: Insulin Sensitivity — 0.1; 0.07 mL/kg/min per uU/mL

Primary: Number of Children With Documented Risk Factors for Type 2 Diabetes — 283; 282 Participants

Primary: Residual Beta-cell Function (RBCF) — 1.78; 2.27; 1.56; 1.76 ng/ml — p=<0.001

Primary: Change in C-peptide Measurement as Reflection of Insulin Secretion at 6 Months — -0.07; -0.07 nmol/L*120 min

Primary: Changes in Beta Cell Function Assessed by Fasting and Stimulated C-peptide Measured at 36 Months. — -0.4; -1.4; 0.1; 0.3 ng per ml

Primary: Children With T1D Underwent a Single Autologous UCB Transfusion — -0.6 ng /ml /120 min — p=>0.05

Primary: Change in the Frequency of Hyper- and Hypo-glycemic Events From Baseline to Week 8-12. — -18; -7.5 Events

Primary: Effect of Anakinra Treatment on PBMC Gene Expression for Patients — 0 probe sets

Primary: Percent of Participants That Achieved Insulin Independence With Adequate Control of Blood Glucose Levels at One Year Post Final Islet Transplantation. — 44; 14; 17; 14…

Primary: Percentage of Time in Target Range of 70-180 mg/dL. — 49.64; 48.86; 60.78; 50.1 percent time spent 70 mg/dL - 180 mg/dL

Primary: Change in Metabolic Function Baseline to 12 Months. — 0.74; 0.43 nmol/L/min — p=0.017

Primary: Change in C-peptide Area Under the Curve Measured by Mixed-meal Tolerance Test (MMTT) Between Group on GFD and Standard Gluten-containing Diet. — 1539; 1173 pmol*min/l…

Primary: HbA1c Value After 28 Days — 7.94; 8.72 HbA1c %

Primary: Glycemic Control (A1C) — 8.60; 9.35 percentage of glycosylated hemoglobin — p=0.593

Primary: Change From Baseline in Total, Basal, and Bolus Exogenous Insulin Requirements — -2.09; 2.83; -1.92; -1.10 mg/dL

Primary: Change in C-peptide ln(AUC+1) Standardized by Duration of the Mixed Meal Tolerance Test (MMTT) — -0.2112; -0.0859; -0.2185; -0.0800 pmol/mL — p=<0.001